ArticleJournal of public health research2025
Orthopoxvirus zoonosis: A potential threat across the Balkan countries.
Article in Journal of public health research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Serological evidence uncovers undocumented mpox exposure in febrile patients in Nigeria.Frontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Monkeypox disease (mpox) is an endemic zoonosis, previously restricted to Central and Western African countries. Since 2022, it is the most common orthopoxvirus (OPXV) zoonotic disease observed in non-endemic countries, including Europe and America, and 333 cases of mpox were already confirmed in the Balkan countries. To monitor and control the spread of mpox, a surveillance program was established in line with WHO guidelines. Although the risk of disease has diminished, sporadic cases still occur. The reemergence of mpox cases at the end of 2024 in Greece, where the first case was registered at the end of May 2022, and the first case recorded in Kosovo raised concerns about a potential outbreak of mpox in the Balkans. Here, we describe the clinical data of significant cases to provide a better understanding in terms of epidemiology, clinical symptoms and diagnostic methods for the detection of this disease. Our results reveal that mpox was diagnosed mainly among young and middle-aged men and people with high-risk behaviors, mostly as coinfections with the human immunodeficiency virus (HIV). This suggests that measures for effective tracing as well as vaccination of high-risk groups of the population are essential pillars to control mpox outbreaks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.